Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Ombitasvir/Paritaprevir/r + Dasabuvir + Sofosbuvir in HCV
NCT02399345Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2015
- Primary completion
- Nov 2015
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of ombitasvir, paritaprevir, dasabuvir, sofosbuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Mar 2015; status: completed.
02
Drugs
ombitasvirparitaprevirdasabuvirsofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02399345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399345.